| Revenue: guided vs achieved | 16.00% achieved Guided 12.00%–13.00%, 23.1% above the top of the range; confirmed by management |
|---|---|
| EBITDA Margin guidance | 1.7% → 1.9% Raised by 0.2 percentage points |
| Management target | Revenue 16.0% FY27 |
| Revenue growth | 16% YoY growth, exceeding historical 12-13% organic trend. |
|---|---|
| Margins | EBITDA margin expanded 180 bps YoY to 27.2% in Q2. |
| Demand visibility | Strong; structural shift toward organized players and chronic disease management. |
| Management confidence | High; emphasizing operational efficiency and high-end specialty testing dominance. |
Growth
Revenue grew 16% YoY, driven by 10% patient volume and 11% test volume increases. B2C and specialty segments saw high-teens growth.
Outlook
EBITDA margins guided to expand 125-170 bps for FY27; price hike planned for Q4 FY27.
Risks
Pricing revisions planned for Q4 could impact volumes if competitors don't follow; initial M&A integration typically sees margin dips.
Last quarter's promises, checked
Delivered
- Rev growth guided 14-15% ex-price/M&A → 16% (= BEAT)
- Specialty to outgrow total → specialty +20% vs 16% total (= BEAT)
- EBITDA margin 27-28% in 2-3 yrs from 24.4% → 27.2% in Q2 (= BEAT)
Partly delivered
- 100 mini-hubs in ~2 yrs, 50 in Y1 → no hub count disclosed; only Insta 60 home-visit launch (= PARTIAL)
Missed
- 250-300 centres added per qtr → 116 new centres (= MISS)
Earnings Call Transcript filed with NSE, NSE: METROPOLIS. Summary written with AI assistance from the document.
Metropolis Healthcare Ltd: key numbers
- Share price
- ₹575.00
- Market cap
- ₹11,929 Cr
- Revenue (annual)
- ₹1,646 Cr
- Net profit (annual)
- ₹190.0 Cr
- P/E (TTM)
- 53.2×Sector 53.8×
- Promoter holding
- 47.82%-1.04% QoQ
- FII holding
- 11.67%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Metropolis Healthcare Ltd
All →Metropolis Healthcare Dividend
Metropolis Healthcare declared an interim dividend of ₹1 per equity share for FY 26-27. The record date is 9 November 2026.
Metropolis Healthcare Results Update
Metropolis Healthcare posted Q2 FY27 revenue up 16% to ₹497 crore and PAT up 43% to ₹75 crore. Board declared a ₹1 per share interim dividend.
Metropolis Healthcare Investor Presentation: Key Takeaways
Q2 FY27 revenue INR 497 Cr (+16% YoY), EBITDA INR 135 Cr at 27.2% margin, PAT INR 75 Cr (+43%). H1 revenue INR 947 Cr (+16%). Strategy is Metropolis 3.0, focused on tech, science and profitable growth.
Metropolis Healthcare Q2 FY27 Results: Net Profit ₹75.5 Cr, Up 42.7% YoY
Metropolis Healthcare Ltd reported revenue from operations of ₹496.8 Cr (+15.8% YoY) and net profit of ₹75.5 Cr (+42.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹75.5 Cr · +42.7% YoY
Metropolis Healthcare Employee Stock Options
Metropolis Healthcare granted 24,060 RSUs and 3,58,920 ESOPs under its 2025 plans, and allotted 65,600 shares under its RSU Plan 2020.
Metropolis Healthcare Board Meeting Date
Metropolis Healthcare intimated a board meeting on November 3, 2026 to consider Q2 and half-year unaudited results and possible interim dividend. Trading window is closed October 1 to November 5, 2026.